期刊文献+

生长抑素、垂体后叶素与奥美拉唑三联疗法对肝硬化伴食管-胃底静脉曲张破裂出血患者胃泌素、胰高血糖素及血流动力学影响 被引量:31

Study on the effects of Somatostatin, Pituitrin and Omeprazole triple therapy in the treatment of cirrhosis with hemorrhage of gastroesophageal varices in serum GAS, GLC and hemodynamics
在线阅读 下载PDF
导出
摘要 目的探讨生长抑素、垂体后叶素与奥美拉唑三联疗法对肝硬化伴食管-胃底静脉曲张破裂出血(EGVB)患者胃泌素(GAS)、胰高血糖素(GLC)及血流动力学影响。方法选择2012年12月1日~2016年6月5日辽宁中医药大学附属医院急诊治疗的肝硬化伴EGVB患者117例,根据治疗方案分为生长抑素组、垂体后叶素组和联合组,每组各39例。生长抑素组采用生长抑素+奥美拉唑,垂体后叶素组采用垂体后叶素+奥美拉唑,联合组采用生长抑素+垂体后叶素+奥美拉唑,时间维持24~48 h。对中心静脉压、门静脉压、门静脉内径、门静脉血流速度等进行测定,采血测定GAS、GLC含量,对比两组治疗效果,同时动态监测病情变化,观察不良反应事件及处理经过。结果与治疗前比较,三组治疗后门静脉压(PVP)、门静脉内径(DPV)值、GAS、GLC含量均降低,差异均有统计学意义(P<0.05);与垂体后叶素组、生长抑素组比较,联合组治疗后PVP、DPV值较低,GAS、GLC含量较低,差异均有统计学意义(P<0.05);垂体后叶素组、生长抑素组改善率为74.36%、71.79%,低于联合组(92.31%)(P<0.05);垂体后叶素组、生长抑素组的止血时间、平均输血量及住院时间均高于联合组,差异均有统计学意义(P<0.05)。结论生长抑素、垂体后叶素与奥美拉唑三联疗法可以提高肝硬化伴EGVB的止血效果,降低门脉压力、调节胃肠激素,值得广泛推广。 Objective To investigate the effects of Somatostatin, Pituitrin and Omeprazole triple therapy in the treatment of cirrhosis with hemorrhage of gastroesophageal varices in serum GAS, GLC and hemodynamics. Methods From December 1, 2012 to June 5, 2016, 117 cases of cirrhosis with hemorrhage of gastroesophageal varices were collected in the Affiliated Hospital of Liaoning University of Traditional Chinese Medicine, according to the type of treatment,were randomly divided into Somatostatin group, Pituitrin group and combined group, with 39 cases in each group, Somatostatin group was treated with Somatostatin+Omeprazole, Pituitrin group were treated with Pituitrin+Omeprazole and the combined group were treated with Somatostatin+Pituitrin+Omeprazole, and three groups were treated for 24 to 48 h.The pressure, portal venous pressure, portal vein diameter, portal vein blood flow velocity of central vein were measured, the determination of GAS and GLC in blood samples were collected and clinical effect, dynamic changes, adverse events were compared after treatment. Results Compared with that before treatment, PVP, DPV value, GAS, and GLC of the three groups after treatment decreased, the differences were statistically significant(P〈0.05). Compared with Pituitrin group and Somatostatin group, levels of PVP and DPV were lower, GAS and GLC were lower, the differences were statistically significant(P〈0.05). The improved rate of the Pituitrin group(74.36%) and Somatostatin group (71.79%) were lower than the combined group(92.31%),the difference was statistically significant(P〈0.05).The hemostatic time, average blood transfusion and hospitalization time of the Pituitrin group and the Somatostatin group were higher than the combined group(P〈0.05). Conclusion Somatostatin, Pituitrin and Omeprazole triple therapy can improve the liver cirrhosis with esophageal and gastric variceal bleeding bleeding, reduce portal vein pressure,gastrointestinal hormone, is a kind of effective treatment.
作者 李超 LI Chao(Department of Emergency Center, Affiliated Hospital of Liaoning University of Traditional Chinese Medicine, Liaoning Province, Shenyang 110034, China)
出处 《中国医药导报》 CAS 2018年第13期67-71,共5页 China Medical Herald
关键词 生长抑素 垂体后叶素 奥美拉唑 肝硬化 食管-胃底静脉曲张破裂出血 胃肠激素 血流动力学 Somatostatin Pituitrin Omeprazole Cirrhosis Gastroesophageal variceal Bleeding Gastrointestinal hormones Hemodynamics
作者简介 李超(1984.2-),男,硕士;研究方向:消化疾病的临床诊疗。
  • 相关文献

参考文献4

二级参考文献27

  • 1骆丹东.奥美拉唑和奥曲肽联合治疗肝硬化并上消化道出血疗效观察[J].江西医药,2005,40(1):55-56. 被引量:16
  • 2奥曲肽协作组.国产与进口奥曲肽治疗肝硬化食管胃底静脉曲张出血的多中心随机双盲临床研究[J].中华消化杂志,2005,25(8):492-493. 被引量:54
  • 3Maruyama H,Sanyal AJ. Portal hypertention: Nonsurgical andsurgical management. In Schiff ER, Maddrey WC & ScorrellMF eds. Schiff’s Diseases of the Liver, 11th edition. JohnWiley & Sons,Ltd 2012:326-361.
  • 4王吉耀.循证胃肠病学和肝病学(10版).北京:人民卫生出版社,2012:495-531.
  • 5Lo GH,Chen WC,Wang RH,et ai. Controlled trial of ligationplus nadolol versus nadolol alone for the prevention of firstvariceal bleeding. Hepatology,2010;52( 1 ):230-237.
  • 6Imperiale TF,Klein RW,Chalasani N. Cost-effectiveness analy-sis of bleeding vs. beta -blockers for primary prevention ofvariceal bleeding. Hepatology, 2007,45 (4) :870-878.
  • 7Burroughs AK,Triantos CK,O^Beirne J,et al.Predictors of earlyrebleeding and mortality after acute variceal hemorrhage inpatients with cirrhosis. Nat Clin Pract Gastroenterol Hepatol,2009,6(2):72-73.
  • 8Ravipati M, Katragadda S, Swaminathan PD,et al. Pharma-cotherapy plus endoscopic intervention is more effective thanpharmacotherapy or endoscopic alone in the secondary pre-vention of esophageal variceal bleeding: a meta -analysis ofrandomized,controlled trials. Gastrointest Endosc,2009,70(4):658-664.
  • 9Misshra SR , Chander SB , KumarA, S, et al. Endoscopiccyanoacrylate injection versus beta -blocker for secondaryprophylaxis of gastric variceal bleed:a randomized controlledtrial. Gut,2010,59(6):729-735.
  • 10Tripathi D, Ferguson JW, Kochar N, et al .Randomized controlledtrial of carvedilol versus variceal band ligation for the preven-tion of the first variceal bleed. Hepatology, 2009,50 (3):825-833.

共引文献30

同被引文献289

引证文献31

二级引证文献152

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部